Alendronic Acid
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Alendronic Acid |
| DrugBank ID | DB00630 |
| Brand Names (EU) | Alendronic acid |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.27% |
Approved Indication (EMA)
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Fosavance reduces the risk of vertebral and hip fractures.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bone Paget disease | 99.27% | DL |
| 2 | HIV infectious disease | 96.78% | DL |
| 3 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 95.23% | DL |
| 4 | simian immunodeficiency virus infection | 94.82% | DL |
| 5 | feline acquired immunodeficiency syndrome | 94.82% | DL |
| 6 | deficiency anemia | 94.25% | DL |
| 7 | juvenile Paget disease | 93.31% | DL |
| 8 | vitamin B12- and folate-independent constitutional megaloblastic anemia | 90.61% | DL |
| 9 | Plummer-Vinson syndrome | 90.37% | DL |
| 10 | osteomesopyknosis | 88.17% | DL |
| 11 | obsolete familial combined hyperlipidemia | 86.32% | DL |
| 12 | biotin metabolic disease | 86.15% | DL |
| 13 | Paget disease of bone | 85.55% | DL |
| 14 | primary release disorder of platelets | 84.73% | DL |
| 15 | pseudo-von Willebrand disease | 84.32% | DL |
| 16 | Paget disease of bone 2, early-onset | 81.90% | DL |
| 17 | penile fibromatosis | 79.95% | DL |
| 18 | vitamin deficiency disorder | 78.22% | DL |
| 19 | palmar fibromatosis | 77.54% | DL |
| 20 | infantile digital fibromatosis | 76.26% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.